| abstract |
The present disclosure generally relates to compositions comprising an antibody that specifically binds to a SIRPĪ²1 polypeptide, e.g., human SIRPĪ²1, e.g., a monoclonal, antibody, antibody fragment, and the like, and to prevent or , To reduce the risk, or to the use of such compositions in the treatment. |